SCHEMBL3628640

SCHEMBL3628640

CCC[CH]N1CCC(c2ccccc2)(c2ccccc2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 8/20 0.50
GRIN2D O15399 1/20 0.50
GRIN3B O60391 1/20 0.50
CHRM2 P08172 1/20 0.50
CHRM1 P11229 1/20 0.50
GRIN1 Q05586 1/20 0.50
KCNH2 Q12809 1/20 0.50
GRIN2A Q12879 1/20 0.50
GRIN2B Q13224 1/20 0.50
GRIN2C Q14957 1/20 0.50
GRIN3A Q8TCU5 1/20 0.50
CYP2D6 P10635 1/20 0.50
DRD4 P21917 1/20 0.47
ADRA1A P35348 1/20 0.41
MEN1 O00255 1/20 0.39
CYP2C9 P11712 1/20 0.39
KMT2A Q03164 1/20 0.39
HRH3 Q9Y5N1 1/20 0.37
LMNA P02545 1/20 0.36
OPRD1 P41143 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10864548 0.79 OPRM1 (0.49) OPRM1GRIN2DGRIN3BCHRM2CHRM1
SCHEMBL3867146 0.75 OPRM1 (0.55) OPRM1GRIN2DGRIN3BCHRM2CHRM1
SCHEMBL11742871 0.74 OPRM1 (0.56) OPRM1GRIN2DGRIN3BCHRM2CHRM1
SCHEMBL8765862 0.72 MEN1 (0.47) OPRM1GRIN2DGRIN3BCHRM2CHRM1
SCHEMBL11740559 0.72 ADRA1A (0.57) OPRM1GRIN2DGRIN3BCHRM2CHRM1
SCHEMBL13801224 0.72 OPRM1 (0.53) OPRM1GRIN2DGRIN3BCHRM2CHRM1
SCHEMBL3629706 0.71 DRD2 (0.58) KCNH2DRD4MEN1KMT2ALMNA
SCHEMBL11738164 0.71 OPRM1 (0.77) OPRM1GRIN2DGRIN3BCHRM2CHRM1
SCHEMBL7532189 0.71 OPRM1 (0.49) OPRM1GRIN2DGRIN3BCHRM2CHRM1
SCHEMBL11744408 0.71 OPRM1 (0.56) OPRM1KCNH2DRD4ADRA1AHTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1487444-B9 USE OF PYRIDYL AMIDES AS INHIBITORS OF ANGIOGENESIS ASTELLAS DEUTSCHLAND GMBH (DE) 2010-07-21 EP claimed
EP-1487444-B1 USE OF PYRIDYL AMIDES AS INHIBITORS OF ANGIOGENESIS ASTELLAS DEUTSCHLAND GMBH (DE) 2009-12-30 EP claimed
US-20060052419-A1 Use of pyridly amides as inhibitors of angiogenesis ASTELLAS DEUTSCHLAND GMBH (DE) 2006-03-09 US claimed
EP-1348434-A1 Use of pyridyl amides as inhibitors of angiogenesis Fujisawa Deutschland GmbH (DE) 2003-10-01 EP claimed
EP-1487444-B9 USE OF PYRIDYL AMIDES AS INHIBITORS OF ANGIOGENESIS ASTELLAS DEUTSCHLAND GMBH (DE) 2010-07-21 EP disclosed
EP-1487444-B1 USE OF PYRIDYL AMIDES AS INHIBITORS OF ANGIOGENESIS ASTELLAS DEUTSCHLAND GMBH (DE) 2009-12-30 EP disclosed
US-20060052419-A1 Use of pyridly amides as inhibitors of angiogenesis ASTELLAS DEUTSCHLAND GMBH (DE) 2006-03-09 US disclosed
EP-1348434-A1 Use of pyridyl amides as inhibitors of angiogenesis Fujisawa Deutschland GmbH (DE) 2003-10-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060052419-A1 Use of pyridly amides as inhibitors of angiogenesis FLT1, VEGFA, FLT4 OPRM1 3045/4885GRIN2D 4615/4885GRIN3B 4338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.